| Date Filed | Type | Description |
| 10/12/2023 |
10-Q
| Quarterly Report for the period ended August 31, 2023 |
| 10/02/2023 |
EFFECT
| Form EFFECT - Notice of Effectiveness: |
| 09/27/2023 |
DEF 14A
| Form DEF 14A - Other definitive proxy statements: |
| 08/25/2023 |
10-K
| Annual Report for the period ended May 31, 2023 |
| 08/18/2023 |
3
| Form 3 - Initial statement of beneficial ownership of securities: |
| 07/26/2023 |
8-K
| Quarterly results |
| 07/03/2023 |
5
| BARBIERI ALLEN (Vice Chairman) has filed a Form 5 on BIOMERICA INC |
| 05/26/2023 |
4
| Irani Zackary S. (CEO) has filed a Form 4 on BIOMERICA INC|
Txns:
| Bought 500 shares
@ $1.61, valued at
$805
Bought 200 shares
@ $1.55, valued at
$310 |
|
| 05/12/2023 |
4
| Irani Zackary S. (CEO) has filed a Form 4 on BIOMERICA INC|
Txns:
| Bought 1,700 shares
@ $1.17, valued at
$2k
|
|
| 05/10/2023 |
4
| Irani Zackary S. (CEO) has filed a Form 4 on BIOMERICA INC|
Txns:
| Bought 300 shares
@ $1.39, valued at
$417 |
|
| 05/05/2023 |
4
| Form 4 - Statement of changes in beneficial ownership of securities: |
| 05/01/2023 |
4
| Irani Zackary S. (CEO) has filed a Form 4 on BIOMERICA INC|
Txns:
| Bought 2,600 shares
@ $1.31, valued at
$3.4k
Bought 1,800 shares
@ $1.34, valued at
$2.4k
|
|
| 04/27/2023 |
4
| Form 4 - Statement of changes in beneficial ownership of securities: |
| 04/25/2023 |
8-K
| Quarterly results |
| 04/14/2023 |
10-Q
| Quarterly Report for the period ended February 28, 2023 |
| 03/09/2023 |
3
| Lu Gary (CFO) has filed a Form 3 on BIOMERICA INC |
| 03/07/2023 |
8-K
| Entry into a Material Definitive Agreement, Regulation FD Disclosure, Financial Statements and Exhibits Inte...|
Docs:
|
"BIOMERICA, INC. UNDERWRITING AGREEMENT",
"Letter re: Shares of Common Stock of Biomerica, Inc.",
"Biomerica Announces Proposed Underwritten Public Offering of Common Stock",
"Biomerica Announces Pricing of $8 Million Underwritten Public Offering of Common Stock",
"Biomerica Announces Closing of $8 Million Underwritten Public Offering of Common Stock IRVINE, Calif., March 07, 2023-Biomerica, Inc. , a global provider of advanced medical products, announced today the closing of its previously announced underwritten public offering of an aggregate of 3,333,333 shares of its common stock, par value $0.08 per share, at a price to the public of $2.40 per sharefor total gross proceeds of $8 million, before deducting underwriting discounts and commissions and other offering-related expenses payable by Biomerica. All of the shares of common stock sold in the offering were offered by Biomerica. Craig-Hallum Capital Group LLC acted as sole managing underwriter in connection with the offering. Biomerica intends to use the net proceeds of the offering for general..." |
|
| 03/02/2023 |
424B5
| Form 424B5 - Prospectus [Rule 424(b)(5)]: |
| 03/02/2023 |
424B5
| Form 424B5 - Prospectus [Rule 424(b)(5)]: |
| 03/02/2023 |
8-K
| Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements... |
| 02/14/2023 |
SC 13G/A
| Granahan Investment Management, LLC reports a 8.4% stake in BIOMERICA, INC. |
| 02/07/2023 |
8-K
| Investor presentation |
| 01/31/2023 |
4
| BARBIERI ALLEN (Executive Vice Chairman) has filed a Form 4 on BIOMERICA INC|
Txns:
| Bought 1,538 shares
@ $2.94, valued at
$4.5k
|
|
| 01/30/2023 |
4
| Coste Catherine (Director) has filed a Form 4 on BIOMERICA INC|
Txns:
| Bought 2,190 shares
@ $2.96, valued at
$6.5k
|
|
| 01/26/2023 |
4
| Irani Zackary S. (CEO) has filed a Form 4 on BIOMERICA INC|
Txns:
| Bought 1,800 shares
@ $2.85, valued at
$5.1k
|
|
| 01/25/2023 |
4
| Irani Zackary S. (CEO) has filed a Form 4 on BIOMERICA INC|
Txns:
| Bought 2,000 shares
@ $2.81, valued at
$5.6k
|
|
| 01/13/2023 |
10-Q
| Quarterly Report for the period ended November 30, 2022 |
| 12/29/2022 |
8-K/A
| Quarterly results |
| 12/16/2022 |
8-K
| Quarterly results |
| 12/16/2022 |
8-K
| Quarterly results |
| 12/09/2022 |
8-K
| Quarterly results |
| 12/09/2022 |
8-K
| Quarterly results |
| 11/14/2022 |
8-K
| Quarterly results |
| 10/13/2022 |
10-Q
| Quarterly Report for the period ended August 31, 2022 |
|